Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03709342 · ClinicalTrials.gov registry record · Phase 2
A PK/PD Study of CM4620-IE in Patients With Acute Pancreatitis
A Phase 2 study, sponsored by CalciMedica.
- Completed
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT03709342 is a Phase 2 study that has completed, run by CalciMedica. The registered enrollment target is 7 participants.
The verdict
NCT03709342, a Phase 2 study, has completed, sponsored by CalciMedica.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
This open-label study will evaluate the pharmacodynamic and pharmacokinetic profile of CM4620-IE in patients with acute pancreatitis. The first five (5) patients will receive ≤ 2.08 mg/kg of CM4620-IE by continuous IV infusion on Day 1. If necessary, up to an additional 4 patients may be treated at a different dose of CM4620-IE as determined by the obtained PK and PD data. The infusion of CM4620-IE will start within 12 hours from the time the patient or LAR provides informed consent.
Interventions
- DRUG CM4620-IE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2019-01-06 |
| Est. Completion | 2019-06-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03709342
The ClinicalTrials.gov registry entry for NCT03709342 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CalciMedica, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CM4620-IE is the first listed.
NCT03709342 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03709342 about?
NCT03709342 is a clinical study titled "A PK/PD Study of CM4620-IE in Patients With Acute Pancreatitis". This open-label study will evaluate the pharmacodynamic and pharmacokinetic profile of CM4620-IE in patients with acute pancreatitis. The first five (5) patients will receive ≤ 2.08 mg/kg of CM4620-IE by continuous IV infusion on Day 1. If necessary, up to an additional 4 patients may be treated at ...
What is the current status of trial NCT03709342?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2019-01-06. Estimated completion is 2019-06-07.
What interventions are being tested in trial NCT03709342?
The interventions under investigation include: CM4620-IE (DRUG).
Who is sponsoring clinical trial NCT03709342?
This trial is sponsored by CalciMedica, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.